Dr. Reddy's Laboratories Ltd. (RDY)

37.05
0.80 2.21
NYSE : Health Technology
Prev Close 36.25
Open 37.12
Day Low/High 36.93 / 37.41
52 Wk Low/High 29.00 / 42.82
Volume 192.32K
Avg Volume 163.00K
Exchange NYSE
Shares Outstanding 166.01M
Market Cap 6.10B
EPS 1.60
P/E Ratio 22.60
Div & Yield 0.29 (0.74%)
Dr. Reddy's Laboratories Announces Entering Into A Definitive Agreement To Sell Its Neurology Branded Products To Upsher-Smith Laboratories, LLC

Dr. Reddy's Laboratories Announces Entering Into A Definitive Agreement To Sell Its Neurology Branded Products To Upsher-Smith Laboratories, LLC

Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announces that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to which Dr.

Upsher-Smith Laboratories Enters Into Agreement To Acquire Tosymra™ (sumatriptan Nasal Spray) And Zembrace® SymTouch® (sumatriptan Injection)

Upsher-Smith Laboratories Enters Into Agreement To Acquire Tosymra™ (sumatriptan Nasal Spray) And Zembrace® SymTouch® (sumatriptan Injection)

Strategic Acquisition Diversifies Company's Portfolio and Provides New Options for Migraine Patients

Dr. Reddy's Laboratories Limited Announces Filing Of Annual Report On Form 20-F

Dr. Reddy's Laboratories Limited Announces Filing Of Annual Report On Form 20-F

Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended March 31, 2019 was filed with the United States...

An Auction House, a Chemical Maker and Other Stocks That Look Good Short

BID, TWOU, RDY, ALB and PTR all recently were downgraded by TheStreet's Quant Ratings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AEL, FBK, FRO, NODK, OPBK Downgrades: ALB, APYX, BHE, CREE, MEDP, NTWK, PPDF, RDY, SINO, SVM, SVT, SVVC, TPC, TPCO Initiations: CLBK, LEVL, MOR Read on to get TheStreet Quant Ratings' detailed report:

Dr. Reddy's Q4 & FY19 Financial Results

Dr. Reddy's Q4 & FY19 Financial Results

Dr. Reddy's Laboratories Ltd.

URGENT: Monteverde & Associates PC Invites Dr. Reddy's Laboratories Ltd. Shareholders Or Former Shareholders To Contact The Firm Immediately

URGENT: Monteverde & Associates PC Invites Dr. Reddy's Laboratories Ltd. Shareholders Or Former Shareholders To Contact The Firm Immediately

NEW YORK, May 1, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City announces that it is investigating Dr.

Dr. Reddy's To Release Q4 And Full Year FY 19 Results On May 17, 2019

Dr. Reddy's To Release Q4 And Full Year FY 19 Results On May 17, 2019

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Announces Acquisition Of ANDA Portfolio

Dr. Reddy's Laboratories Announces Acquisition Of ANDA Portfolio

Dr. Reddy's Laboratories Ltd.

Promius Pharma, LLC. (a Wholly Owned Subsidiary Of Dr. Reddy's Laboratories Ltd.) Announces The Sale And Assignment Of The US Rights For Its Marketed Dermatology Brands To Encore Dermatology

Promius Pharma, LLC. (a Wholly Owned Subsidiary Of Dr. Reddy's Laboratories Ltd.) Announces The Sale And Assignment Of The US Rights For Its Marketed Dermatology Brands To Encore Dermatology

Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr.

Dr. Reddy's Laboratories Launches Tadalafil Tablets USP In The U.S. Market

Dr. Reddy's Laboratories Launches Tadalafil Tablets USP In The U.S. Market

Dr. Reddy's Laboratories Ltd.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, DGII, FLWS, JVA, LBRDA, MUR, OLP, RDY, SGEN, TESS, TWIN, VMC, YRCW Downgrades: CRUS, MINI, USLM, ZBH Initiations: CBTX, MBIN, SOGO Read on to get TheStreet Quant Ratings' detailed report:

Dr. Reddy's Q3 FY19 Financial Results

Dr. Reddy's Q3 FY19 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's To Release Q3 FY19 Results On February 1, 2019

Dr. Reddy's To Release Q3 FY19 Results On February 1, 2019

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the quarter ended December 31, 2018 on Friday, February 1, 2019 after the Board Meeting.

Dr. Reddy's Laboratories Limited To Present At The 37th Annual J.P. Morgan Healthcare Conference

Dr. Reddy's Laboratories Limited To Present At The 37th Annual J.P. Morgan Healthcare Conference

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will be presenting at the 37th Annual J.

Dr. Reddy's Laboratories Launches Aspirin And Extended-Release Dipyridamole Capsules In The U.S. Market

Dr. Reddy's Laboratories Launches Aspirin And Extended-Release Dipyridamole Capsules In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as "Dr.

Dr. Reddy's Q2 & H1 FY19 Financial Results

Dr. Reddy's Q2 & H1 FY19 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Receives Approval For Aspirin And Extended-Release Dipyridamole Capsules In The U.S. Market

Dr. Reddy's Laboratories Receives Approval For Aspirin And Extended-Release Dipyridamole Capsules In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr.

TheStreet Quant Rating: C (Hold)